UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Modeling Alzheimer's Disease Progression Using Disease Onset Time and Disease Trajectory Concepts Applied to CDR‐SOB Scores From ADNI

CPT: pharmacometrics and systems pharmacology, 2013-10, Vol.2 (10), p.1-10

2013

Volltextzugriff (PDF)

Modelling response time profiles in the absence of drug concentrations: definition and performance evaluation of the K-PD model

Journal of pharmacokinetics and pharmacodynamics, 2007-02, Vol.34 (1), p.57-85

2007

Volltextzugriff (PDF)

Clinical utility of a pharmacostatistical model for ibandronate in postmenopausal osteoporosis

Current drug metabolism, 2006-10, Vol.7 (7), p.827-836

2006

Volltextzugriff (PDF)

Population pharmacokinetics of ibandronate in Caucasian and Japanese healthy males and postmenopausal females

International journal of clinical pharmacology and therapeutics, 2006-12, Vol.44 (12), p.655-667

2006

Volltextzugriff (PDF)

Explicit solutions for a class of indirect pharmacodynamic response models

Computer methods and programs in biomedicine, 2005-02, Vol.77 (2), p.91-97

2005

Volltextzugriff (PDF)

Pharmacometrics : modelling and simulation tools to improve decision making in clinical drug development

European journal of drug metabolism and pharmacokinetics, 2000-01, Vol.25 (1), p.49-58

2000

Volltextzugriff (PDF)

Interactive Visualization and Communication for Increased Impact of Pharmacometrics

Journal of clinical pharmacology, 2010-09, Vol.50 (S9), p.140S-145S

2010

Volltextzugriff (PDF)

Population pharmacokinetic analysis of the major metabolites of capecitabine

Journal of pharmacokinetics and pharmacodynamics, 2002-02, Vol.29 (1), p.25-47

2002

Volltextzugriff (PDF)

A semimechanistic and mechanistic population PK–PD model for biomarker response to ibandronate, a new bisphosphonate for the treatment of osteoporosis

British journal of clinical pharmacology, 2004-12, Vol.58 (6), p.618-631

2004

Volltextzugriff (PDF)

Population pharmacokinetics and concentration–effect relationships of capecitabine metabolites in colorectal cancer patients

British journal of clinical pharmacology, 2003-03, Vol.55 (3), p.252-263

2003

Volltextzugriff (PDF)

Pharmacokinetic and pharmacodynamic interactions of bretazenil and diazepam with alcohol

British journal of clinical pharmacology, 1996-06, Vol.41 (6), p.565-573

1996

Volltextzugriff (PDF)

Exploring clinical study design by computer simulation based on pharmacokinetic/pharmacodynamic modelling

International journal of clinical pharmacology and therapeutics, 1997-10, Vol.35 (10), p.469

1997

Volltextzugriff (PDF)

Relationships between exposure to saquinavir monotherapy and antiviral response in HIV-positive patients

Clinical pharmacokinetics, 1999-07, Vol.37 (1), p.75-86

1999

Volltextzugriff (PDF)

Clinical pharmacokinetic/pharmacodynamic and physiologically based pharmacokinetic modeling in new drug development: the capecitabine experience

Investigational new drugs, 2003-05, Vol.21 (2), p.195-223

2003

Volltextzugriff (PDF)

Pharmacodynamic interactions of diazepam and intravenous alcohol at pseudo steady state

Psychopharmacologia, 1993-03, Vol.110 (4), p.471-478

1993

Volltextzugriff (PDF)

Integrated pharmacokinetics and pharmacodynamics of the novel catechol‐O‐methyltransferase inhibitor tolcapone during first administration to humans

Clinical pharmacology and therapeutics, 1995-05, Vol.57 (5), p.508-517

1995

Volltextzugriff (PDF)

Modelling of Serum CTX Levels with Daily and Monthly Oral Ibandronate

Journal of clinical densitometry, 2006-07, Vol.9 (3), p.383-383

2006

Volltextzugriff (PDF)

Ein neues nuklearmedizinisches Verfahren zur Bestimmung des linksventrikulären Schlagvolumens

Nuclear medicine, 1983-06, Vol.22 (6), p.294

1983

Volltextzugriff (PDF)

Modelling of Serum CTX Levels with Daily and Monthly Oral Ibandronate

Journal of clinical densitometry, 2006-04, Vol.9 (2), p.251-251

2006

Volltextzugriff (PDF)

421 A new bio-mathematical model to describe the dynamics of HBV-DNA and infected hepatocytes in HBEAG-negative/anti-HBE-positive chronic hepatitis B patients treated with peginterferon alfa-2A (40KD) (PEGASYS®), lamivudine, or PEGASYS® plus lamivudine combin

Journal of hepatology, 2004, Vol.40, p.125-125

2004

Volltextzugriff (PDF)

Pharmacokinetic and pharmacodynamic interactions between fluoxetine and moclobemide in the investigation of development of the "serotonin syndrome"

Clinical pharmacology and therapeutics, 1998-04, Vol.63 (4), p.403-413

1998

Volltextzugriff (PDF)

Interaction of moclobemide, a new reversible monoamine oxidase inhibitor with oral tyramine

Journal of neural transmission. Supplementum, 1988, Vol.26, p.97

1988

Volltextzugriff (PDF)

Blood pressure response to tyramine-enriched meal before and during MAO-inhibition in man: influence of dosage regimen

Journal of neural transmission. Supplementum, 1988, Vol.26, p.105

1988

Volltextzugriff (PDF)

Moclobemide, a new reversible monoamine oxidase inhibitor, and tyramine interaction studies

Current therapeutic research, 1988-05, Vol.43 (5), p.903-917

1988

Volltextzugriff (PDF)

Potentiation of the pressor effect of oral and intravenous tyramine during administration of the selective MAO-A inhibitor moclobemide in healthy volunteers

Journal of psychopharmacology (Oxford), 1989-01, Vol.3 (1), p.36-44

1989

Volltextzugriff (PDF)

1 – 25 von 41

Suche als RSS-Feed

Aktive Filter

PublikationsformWebseiten

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(40)
Mit Volltextzugriff
(25)

Publikationsform

Artikel
(40)
Tagungsberichte
(1)

Sprache

Englisch
(39)
Deutsch
(2)

Erscheinungsjahr

n.n

Thema

Humans
(25)
Science & Technology
(25)
Life Sciences & Biomedicine
(24)
Pharmacology & Pharmacy
(23)
Biological And Medical Sciences
(15)
Medical Sciences
(15)
Male
(14)
Adult
(13)
Pharmacology. Drug Treatments
(13)
Models, Biological
(11)
Female
(9)
Pharmacokinetics
(9)
Administration, Oral
(8)
Double-Blind Method
(8)
Computer Simulation
(7)
Neuropharmacology
(7)
Pharmacodynamics
(7)
Moclobemide
(6)
Psychology. Psychoanalysis. Psychiatry
(6)
Psychopharmacology
(6)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Modeling Alzheimer's Disease Progression Using Disease Onset Time and Disease Trajectory Concepts Applied to CDR‐SOB Scores From ADNI

Modelling response time profiles in the absence of drug concentrations: definition and performance evaluation of the K-PD model

Clinical utility of a pharmacostatistical model for ibandronate in postmenopausal osteoporosis

Population pharmacokinetics of ibandronate in Caucasian and Japanese healthy males and postmenopausal females

Explicit solutions for a class of indirect pharmacodynamic response models

Pharmacometrics : modelling and simulation tools to improve decision making in clinical drug development

Interactive Visualization and Communication for Increased Impact of Pharmacometrics

Population pharmacokinetic analysis of the major metabolites of capecitabine

A semimechanistic and mechanistic population PK–PD model for biomarker response to ibandronate, a new bisphosphonate for the treatment of osteoporosis

Population pharmacokinetics and concentration–effect relationships of capecitabine metabolites in colorectal cancer patients

Pharmacokinetic and pharmacodynamic interactions of bretazenil and diazepam with alcohol

Exploring clinical study design by computer simulation based on pharmacokinetic/pharmacodynamic modelling

Relationships between exposure to saquinavir monotherapy and antiviral response in HIV-positive patients

Clinical pharmacokinetic/pharmacodynamic and physiologically based pharmacokinetic modeling in new drug development: the capecitabine experience

Pharmacodynamic interactions of diazepam and intravenous alcohol at pseudo steady state

Integrated pharmacokinetics and pharmacodynamics of the novel catechol‐O‐methyltransferase inhibitor tolcapone during first administration to humans

Modelling of Serum CTX Levels with Daily and Monthly Oral Ibandronate

Ein neues nuklearmedizinisches Verfahren zur Bestimmung des linksventrikulären Schlagvolumens

Modelling of Serum CTX Levels with Daily and Monthly Oral Ibandronate

421 A new bio-mathematical model to describe the dynamics of HBV-DNA and infected hepatocytes in HBEAG-negative/anti-HBE-positive chronic hepatitis B patients treated with peginterferon alfa-2A (40KD) (PEGASYS®), lamivudine, or PEGASYS® plus lamivudine combin

Pharmacokinetic and pharmacodynamic interactions between fluoxetine and moclobemide in the investigation of development of the "serotonin syndrome"

Interaction of moclobemide, a new reversible monoamine oxidase inhibitor with oral tyramine

Blood pressure response to tyramine-enriched meal before and during MAO-inhibition in man: influence of dosage regimen

Moclobemide, a new reversible monoamine oxidase inhibitor, and tyramine interaction studies

Potentiation of the pressor effect of oral and intravenous tyramine during administration of the selective MAO-A inhibitor moclobemide in healthy volunteers

Aktive Filter

Suchergebnisse filtern